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Background: There are limited data describing patients with moderate COPD exacerbations and evaluating
comparative effectiveness of maintenance treatments in this patient population. The study examined COPD
patients with moderate COPD exacerbations. COPD-related outcomes were compared between patients initiating
fluticasone propionate-salmeterol 250/50 mcg (FSC) vs anticholinergics (ACs) following a moderate COPD
exacerbation.
Methods: This retrospective observational study used a large administrative claims database (study period:
2003–2009) to identify and describe patients with an initial, moderate COPD exacerbation. A descriptive analysis of
patients with moderate COPD exacerbations was done evaluating maintenance treatment rates, subsequent COPD
exacerbation rates, and COPD-related costs during a 1-year period. A cohort analysis compared COPD exacerbation
rates and associated costs during a variable-length follow-up period between patients initiating maintenance
therapy with FSC or ACs. COPD exacerbations were reported as rate per 100 patient-years, and monthly costs were
reported (standardized to USD 2009). COPD exacerbation rates between cohorts were evaluated using Cox
proportional hazards models, and costs were analyzed using generalized linear models with log-link and gamma
distribution.
Results: 21,524 patients with a moderate COPD exacerbation were identified. Only 25% initiated maintenance
therapy, and 13% had a subsequent exacerbation. Annual costs averaged $594 per patient. A total of 2,849 treated
patients (FSC = 925; AC = 1,924) were eligible for the cohort analysis. The FSC cohort had a significantly lower rate of
COPD exacerbations compared to the AC cohort (20.8 vs 32.8; P= 0.04). After adjusting for differences in baseline
covariates, the FSC cohort had a 42% significantly lower risk of a COPD exacerbation (HR = 0.58; 95% CI: 0.38, 0.91).
The FSC cohort incurred significantly higher adjusted pharmacy costs per patient per month by $37 (95% CI: $19,
$72) for COPD-related medications vs the AC cohort. However, this increase was offset by a significant reduction in
adjusted monthly medical costs per patient for the FSC vs the AC cohort ($82 vs $112; P< 0.05). Total monthly
COPD-related costs, as a result, did not differ between cohorts.
Conclusions: Only a quarter of patients with a moderate COPD exacerbation were subsequently treated with
maintenance therapy. Initiation of FSC among those treated was associated with better clinical and economic
outcomes compared to AC.
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Chronic obstructive pulmonary disease (COPD) is cha-
racterized by limited and irreversible airflow and accom-
panied by a range of pathological changes in the lung
[1]. COPD is associated with significant mortality, as the
Centers for Disease Control and Prevention reported
chronic lower respiratory diseases to be the third-
leading cause of death in the United States (US) in 2009,
accounting for 44.7 deaths per 100,000 persons [2].
In addition to its significant mortality, COPD carries a
substantial economic burden. In the US in 2010, the
total costs of COPD were estimated at $49.9 billion, with
$29.5 billion attributed to direct healthcare expenditures.
Hospitalizations accounted for the largest portion of
direct costs at $13.2 billion, followed by $5.8 billion in
prescription drug costs, and $5.5 billion in physician ser-
vices [3]. Not surprisingly, COPD costs are directly
related to the severity of disease [4, 5]. A study of com-
mercial insurance claims data from the US showed the
cost of a severe exacerbation to be 2.6 times greater than
the cost of a non-severe exacerbation [5].
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) provides a staging system for catego-
rizing severity of stable COPD, and defines stages for
mild, moderate, severe, and very severe disease [1].
Moderate COPD is the most commonly diagnosed stage,
comprising 46% to 54% of all patients with COPD [6–8],
and is defined using spirometry as forced expiratory vol-
ume in one second (FEV1)/forced vital capacity (FVC)
<0.70 and 50% ≤ FEV1 <80% predicted. It is at the
moderate stage that patients typically present for me-
dical care, due to persisting respiratory symptoms or an
acute exacerbation [1]. For patients with moderate
COPD, maintenance therapy with bronchodilators
(inhaled long-acting beta-agonists [LABAs] and anticho-
linergics [ACs]) is recommended [1]. The addition of
inhaled corticosteroid (ICS)-containing drugs is recom-
mended for patients with repeated COPD exacerbations
or those with severe COPD [1]. A post-hoc analysis of a
large, randomized controlled trial (TORCH) has shown
that initiation of maintenance pharmacotherapy with an
ICS-containing drug at earlier disease stages (moderate
vs severe) can potentially modify disease progression in
COPD, and reduce exacerbation rates compared to
placebo [9]. Post-hoc analysis of the TORCH study in a
subset of patients with moderate COPD as defined by
the GOLD stage II (≥50% FEV1) showed that treatment
with ICS-containing drugs (combination of fluticasone
propionate-salmeterol, or fluticasone alone) significantly
reduced the rate of COPD exacerbations by 31% (95%
confidence interval [CI]: 19, 40) compared to placebo.
Preliminary evidence from the TORCH study suggests
a benefit of using ICS-containing drugs in patients with
moderate COPD. However, large randomized trialspowered to analyze the moderate COPD population are
required to provide definitive answers. In the absence of
clinical trial data, we designed a study to evaluate the
impact of specific maintenance therapies for patients
with a moderate COPD exacerbation using administra-
tive claims data. Absence of lung function parameters
(FEV1 and FVC) precluded assessment of COPD sever-
ity, and accordingly, patients with moderate COPD
could not be evaluated, and instead patients with a mod-
erate COPD exacerbation were evaluated. The current
study had a 2-fold purpose: 1) to characterize patients
with moderate COPD exacerbations, and 2) to evaluate
differential COPD exacerbation rates and related costs
between patients initiating maintenance therapy with
fluticasone propionate-salmeterol combination 250/




Data from January 1, 2003 to March 31, 2009 were
extracted from the IMS LifeLink Health Plan Claims
Database for this study. The Database contains data
from over 90 different managed healthcare plans encom-
passing over 60 million lives. The database includes in-
patient and outpatient diagnoses using International
Classification of Diseases, 9th Revision, Clinical Modifi-
cation (ICD-9-CM) codes, procedures using Current
Procedural Terminology (CPT) codes and Healthcare
Common Procedure Coding System (HCPCS) codes,
and both standard and mail-order prescription records.
The payer type distribution for this data source is 80%
commercial, 3% Medicaid, and less than 2% Medicare
Risk, with the remainder categorized as “other.” The
dataset is de-identified, and hence research conducted
with such data is exempt from ethical approval and is
only required to be compliant with the Health Insurance
Portability and Accountability Act.
Sample selection and study design
The study population was composed of patients with
a moderate COPD exacerbation who had not pre-
viously received maintenance therapy. Additionally,
patients were screened to ensure they did not have a
COPD-related (ICD-9-CM codes of chronic bronchitis
[491.xx], emphysema [492.xx], and chronic airway ob-
struction [496.xx]) hospitalization or emergency de-
partment (ED) visit (medical claim with a primary
discharge diagnosis for a hospitalization or primary
diagnosis for ED visit) in the year before their index
moderate COPD exacerbation. Using a previously
defined algorithm [10, 11], a moderate COPD exacer-
bation was characterized as a physician visit with a
primary diagnosis of COPD (ICD-9-CM codes 491.xx,
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ticosteroid (OCS) or antibiotic within 5 days of the
visit. This definition may have captured exacerbations
that would clinically be defined as mild; however, the
events were classified as moderate since the patient
experienced symptoms requiring them to seek medical
attention. The date of the first moderate COPD exacerba-
tion was defined as the index date for each patient. Main-
tenance therapies included ICS mono-therapy, LABA
monotherapy, ICS+LABA combination therapy, and ACs
(including tiotropium and ipratropium alone or in fixed
combination with albuterol).
The study was done in 2 phases to evaluate the
objectives. Phase 1 comprised a descriptive analysis to
characterize patients with moderate COPD exacerba-
tions and evaluated treatment patterns, exacerbation
rates, and COPD-related healthcare utilization and costs
during a 1-year period after the index date. A retrospec-
tive cohort design was employed in Phase 2 to evaluate
the impact of initiation of select COPD maintenance
therapies on outcomes. The cohort study design ensured
temporality of receipt of maintenance therapy to the
outcomes studied. Patients were eligible for the cohort
analysis if they received a study maintenance therapy
within 30 days of their index date (treatment assessment
period) (Figure 1). The 2 cohorts were named FSC
and AC, (which included tiotropium and ipratropium
alone or in fixed combination with albuterol) depen-
ding on the first drug received during the treatment
assessment period (index drug). A variable-length
follow-up period was adopted for the cohort analysis,
where patients were followed until:Jan 1, 2003 
Study Period: Jan 1, 200
Index date identifica
Jan 1, 2004 







Figure 1 Study design - cohort analysis. KEY: AC – anticholinergic; COPD
propionate-salmeterol 250/50 mcg; TA – treatment assessment. a Index dat
as a physician outpatient visit with a primary diagnosis of COPD and includ
physician outpatient visit. They switched (defined as a switch to any COPD-
related maintenance medication different from the
index drug); or
 They discontinued their study medication (defined
as having more than a 60-day gap between the end
of the days’ supply of the preceding prescription and
the fill date of the next consecutive prescription); or
 The end of continuous eligibility; or
 The end of the study period; or
 A maximum follow-up of 1 year was reached
The length of the variable follow-up period could
therefore range from 1 day to 1 year after the 30-day
treatment assessment period.
Patients with a moderate COPD exacerbation who
were aged 40 years or older on their index date and had
continuous health plan eligibility 1 year prior to the
index date (pre-period) were eligible for inclusion for
both the descriptive and cohort analyses. For the de-
scriptive analysis, all patients were required to have con-
tinuous eligibility for the 1-year period after the index
date as well. Patients were excluded from both the de-
scriptive and cohort analyses if they had received main-
tenance therapy (as defined earlier) in the pre-period,
had a diagnosis of COPD during the pre-period (ie, a
diagnosis code in the primary field of 491.xx, 492.xx,
or 496.xx), or if they had an exclusionary comorbid
medical condition (cystic fibrosis [277.0x], bronchiectasis
[494.xx], respiratory cancer [160–163.xx, 231.xx], pul-
monary fibrosis [515.xx], pneumoconiosis [500–505.xx],
sarcoidosis [135.xx], or pulmonary tuberculosis [011.xx])
anytime during the pre- and follow-up periods.3 to March 31, 2009
Feb 28, 2009 
tion period: 
Mar 31, 2009 
Variable-length follow-up 
period (up to 365 days) 
Outcomes







– chronic obstructive pulmonary disease; FSC – fluticasone
e was the date of the first moderate exacerbation, which was defined
ed an oral corticosteroid or antibiotic prescription within 5 days of the




Characteristic TOTAL N=21,524 FSC n=925 AC n=1,924
Age, mean (SD) 57.4 (11.2) 57.0 (10.2) 59.2a (10.6)




East 7,213 (33.5%) 367 (39.7%) 498 (25.9%)
Midwest 7,603 (35.3%) 320 (34.6%) 772 (40.1%)
South 3,250 (15.1%) 138 (14.9%) 324 (16.8%)
West 3,458 (16.1%) 100 (10.8%) 330 (17.2%)
CCI, mean (SD) 0.81 (1.3) 0.87 (1.4) 0.84 (1.3)
Asthma, n (%) 2,054 (9.5%) 156 (16.9%) 209a (10.9%)
URTI, n (%) 6,607 (30.7%) 298 (32.2%) 520a (27.0%)
LRTI, n (%) 4,937 (22.9%) 287 (31.0%) 545 (28.3%)
Number of SABA
canisters, mean (SD)
0.39 (1.8) 0.86 (2.8) 0.52a (1.9)
Number of OCS
prescriptions, mean (SD)
0.35 (1.2) 0.42 (1.2) 0.41 (1.2)
Use of home oxygen
therapy, n (%)
167 (0.8%) 6 (0.6%) 35a (1.8%)
COPD-related pharmacy
costs,b mean (SD)
$85 (165) $102 (160) $83a (171)
Pulmonologist/allergist
care on index date, n (%)
1,072 (5.0%) 86 (9.3%) 114a (5.9%)
KEY: AC – anticholinergic; CCI – Charlson comorbidity index; COPD – chronic
obstructive pulmonary disease; FSC – fluticasone propionate-salmeterol 250/50
mcg; OCS – oral corticosteroid; LRTI – lower respiratory tract infection;
SABA – short-acting beta agonist; SD – standard deviation; URTI – upper
respiratory tract infection.
aSignificant difference between FSC and AC cohorts at level 0.05; all other
comparisons are non-significant.
bPharmacy costs only include costs of non-maintenance medications, as no
maintenance medications are allowed in the pre-period.
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A descriptive analysis was done to profile patients with a
moderate exacerbation in terms of their rate and fre-
quency of COPD exacerbations, COPD-related costs,
and maintenance treatment rates during the 1-year
period after the index date. COPD exacerbations were
defined as a COPD-related hospitalization or ED visit or
a physician visit with an OCS or antibiotic prescription
within 5 days of the visit. COPD-related costs were
valued in 2009 US dollars (USD) and were estimated
using the allowed payment for all COPD-related medical
and pharmacy services. The allowed payment was
chosen because it best represented the actual amount
that the provider was eligible to receive from all parties,
including third-party payers and patients. COPD-related
medical services included medical claims with a primary
diagnosis of COPD and hospitalization claims with a pri-
mary discharge diagnosis of COPD, while COPD-related
prescriptions included ICS, OCS, LABAs, short-acting
beta-agonists (SABAs), ACs, xanthines, fixed-dose com-
binations, and antibiotics.
In the cohort analysis, outcomes and costs were com-
pared between the FSC and AC cohorts. COPD exacer-
bations, as previously defined, were reported as a rate
per 100 person-years of follow-up due to the variability
in follow-up time of patients. Differences between
cohorts in time to COPD exacerbations were evaluated
using Cox proportional hazards models controlling for
potential confounders identified in the pre-period, in-
cluding: age, region, number of SABA canisters, number
of OCS prescriptions, home oxygen therapy, physician
specialty on the index date, comorbid asthma or upper
respiratory tract infection or lower respiratory tract in-
fection, and Charlson comorbidity index (CCI) score.
COPD-related costs, as previously defined, were also
compared between the FSC and AC cohorts. Adjusted
costs and differences in costs were assessed using gene-
ralized linear models (GLMs) with log-link and gamma
distribution controlling for the aforementioned variables,
as well as pre-period COPD-related pharmacy costs
(log-transformed).
All statistical tests performed tested a 2-sided hypothesis
of no difference between groups at a significance level of
0.05. Analyses were conducted with SAS software (version
9.1.3 for Windows; SAS Institute, Cary, NC).
Results
There were 82,749 patients identified with a moderate
COPD exacerbation, and 21,524 patients met the study
selection criteria. Lack of continuous eligibility for med-
ical and pharmacy services in the pre-period was the pri-
mary reason for exclusion from the study (35% of the
initial sample identified). Demographic characteristics
for the total study population for the descriptive analysisand the FSC and AC cohorts for the cohort analysis are
shown in Table 1.
Descriptive analysis
Patients with an index moderate COPD exacerbation
had an average age of 57 years, with a slightly higher
proportion of females (Table 1). The chronic comorbid
burden at baseline was minimal, as noted by a CCI of
less than 1, and only ~10% of the cohort had concomi-
tant asthma. Almost a quarter of patients, however, had
previously experienced a respiratory tract infection.
During the pre-period, use of rescue medications was
less than one canister per month, as was reflected in the
low annual pharmacy costs ($85).
During the 1-year follow-up period, 25.3% (n = 5,445)
of patients received treatment with a maintenance
therapy following their index moderate COPD exacerba-
tion (Table 2). A total of 12.8% (n = 2,751) of the study
population had a subsequent exacerbation of any




Maintenance treatment rate, n (%) 5,445 (25.3%)
COPD exacerbation rate (overall), n (%) 2,751 (12.8%)
Requiring hospitalization/ED visit 417 (1.9%)
Number of COPD exacerbations (overall), mean (SD) 0.18 (0.57)
Requiring hospitalization/ED visit 0.02 (0.15)
Total COPD-related cost per patient, mean (SD)
(pharmacy + medical)
$594 (1,626)
COPD-related pharmacy costs $293 (542)
COPD-related medical costs $301 (1,431)
KEY: COPD – chronic obstructive pulmonary disease; ED – emergency
department; SD – standard deviation.
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tions per patient was 0.18. Patients admitted to the hos-
pital or ED for their exacerbation comprised 1.9% of the
total population, or 15.1% of the 2,751 with a subsequent
exacerbation. Total average annual COPD-related costs
for the study population were $594 per patient, with
costs being composed of slightly greater medical costs
than pharmacy costs.Cohort analysis
A total of 2,849 patients met the selection criteria for
the cohort analysis; 925 in the FSC cohort and 1,924 in
the AC cohort (73.6% ipratropium and 26.4% tiotro-
pium). The 2 cohorts varied in several demographic
characteristics (Table 1) and trended toward more
advanced COPD in the FSC cohort, including signifi-
cantly higher prevalence of comorbid asthma, rescue
medication use, and use of pulmonologist or allergist
care. The mean duration of follow-up was significantly
longer in the FSC compared to the AC cohort (88 days
vs 75 days; P< 0.01).
During the follow-up period, the FSC cohort had a
42% significantly lower risk of any COPD exacerbation










KEY: AC – anticholinergic; CI – confidence interval; COPD – chronic obstructive pulm
ratio.
aAdjusted HRs obtained from Cox proportional hazards model controlling for age, r
cans, number of oral corticosteroid prescriptions, comorbid asthma or upper respira
and physician specialty on the index date.compared to the AC cohort (Table 3). The unadjusted
rate of having any COPD exacerbation per 100 person-
years was 20.8 for the FSC cohort vs 32.8 for the AC
cohort. Only 2.2 and 7.2 COPD exacerbations per 100
person-years required hospitalization or an ED visit in
the FSC and AC cohorts, respectively; the risk of
hospitalization or ED visit was 77% lower in the FSC
cohort (adjusted HR= 0.23; 95% CI: 0.07, 0.84). The total
monthly adjusted COPD-related costs per patient did
not differ significantly between the 2 cohorts (mean dif-
ference = $8; 95% CI: -$2, $35) (Figure 2). Pharmacy
costs per patient per month were significantly higher in
the FSC cohort (mean difference = $37; 95% CI: $19,
$72; P< 0.05), whereas medical costs per patient per
month were significantly lower in the FSC cohort (mean
difference =−$30; 95% CI: -$16, -$53; P< 0.05).
Discussion
In this study, 1 in 4 patients initiated maintenance
therapy with AC, ICS+LABA, ICS monotherapy, or
LABA monotherapy following a moderate COPD ex-
acerbation. Most studies evaluating drug therapy rates in
the COPD population have included use of SABAs
across all severity levels, precluding a comparison with
our study [12, 13]. However, a recent study by Fitch
et al. evaluated drug therapy patterns by severity levels
using a claims-based algorithm, and found that 26% of
patients with moderate COPD in a commercially insured
population were prescribed a long-acting bronchodilator
[8]. Unlike Fitch et al., our study analyzed patients with
a moderate COPD exacerbation, and not necessarily
those with moderate COPD disease, because spirometry
information is not captured in administrative data. An-
other caveat is that Fitch’s estimate excludes ICS-
containing products and ipratropium, the short-acting
AC. In contrast, the current study includes ipratropium,
suggesting that the use of only long-acting bronchodila-
tors may be even lower than what was observed in this
study.
The above data indicate possible under-treatment in a








32.8 P= 0.04 0.58 P= 0.02
(0.38, 0.91)
7.2 P= 0.06 0.23 P= 0.03
(0.07, 0.84)
onary disease; FSC – fluticasone propionate-salmeterol 250/50; HR – hazard
egion, Charlson comorbidity index score, number of short-acting beta-agonist









Figure 2 Adjusted monthly COPD-related mean costs per patient by drug cohorta,b. KEY: AC – anticholinergic; CI – confidence interval;
COPD – chronic obstructive pulmonary disease; FSC – fluticasone propionate-salmeterol 250/50 mcg. aEach cost component was estimated from
separate regression models and represents a predicted, rather than an observed value. Pharmacy and medical costs may not sum to total. Costs
are in 2009 USD. bCosts obtained from generalized linear models with log-link and gamma distribution controlling for age, region, Charlson
comorbidity index score, number of short-acting beta-agonist canisters, number of oral corticosteroid prescriptions, comorbid asthma or upper
respiratory tract infection or lower respiratory tract infection, home oxygen therapy, physician specialty on the index date, and pre-period COPD-
related pharmacy costs (logged). cSignificant difference between FSC and AC (referent group) cohorts at alpha level 0.05.
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experiencing a moderate COPD exacerbation, these
patients were sufficiently ‘mild’ in severity not to have
required maintenance treatment, and maintenance treat-
ment was then reserved for those with subsequent
COPD exacerbations. However, of the 13% of patients
who had a subsequent exacerbation in this study follow-
ing their index moderate COPD exacerbation, only 48%
received maintenance therapy, suggesting sub-optimal
treatment of the COPD population.
Because one of the objectives of maintenance pharma-
cotherapy is preventing COPD exacerbations, therapies
that most effectively prevent COPD exacerbations have
the potential to improve outcomes and decrease costs.
Although there are studies that compare changes in lung
function between maintenance therapy classes for
patients with moderate COPD [14–16], there are limited
data evaluating exacerbation outcomes outside of a clin-
ical trial setting for this COPD subset. There is prelimin-
ary information, albeit in post-hoc analyses, from 2 large
trials comparing maintenance therapies with placebo
that have shown a significant reduction in the COPD ex-
acerbation rate for patients with moderate COPD [9, 17].
However, evidence around head-to-head comparisons is
lacking.
In the absence of comparative clinical trial data, obser-
vational studies using retrospectively collected data
permit evaluation of comparative treatments and provide
for robust sample sizes. This observational studyprovides a valuable evidence base to differentiate among
available maintenance therapies—specifically, the com-
bination of FSC and the AC agents that include tiotro-
pium. This study demonstrated that patients receiving
maintenance therapy with FSC had a 42% significantly
lower risk of exacerbation than patients taking ACs.
Despite the differences in COPD exacerbations between
cohorts, the total monthly cost did not differ between
cohorts. Further examination of the component medical
and pharmacy costs revealed that the FSC cohort had
significantly higher pharmacy costs, whereas the AC co-
hort had significantly higher medical costs. Therefore,
the lower COPD exacerbation rate in the FSC cohort did
result in lower medical costs; however, any cost-savings
were offset by higher drug-acquisition costs. This
population-based study using actuarial claims data pro-
vides much-needed data isolating the costs and impact
of 2 maintenance therapy options.
The study design warrants specific discussion of both
strengths and limitations. Because the study used claims
data, lung function data were not available for use in clas-
sifying the severity of the underlying pre-exacerbation
COPD of the patients enrolled in this study. Therefore, it
is possible that patients with moderate exacerbation have
varying COPD severity levels, and do not necessarily
include patients with moderate COPD. Although this
is a notable limitation, baseline demographic charac-
teristics of the study sample are consistent with that
of patients with moderate COPD exacerbations,
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The inclusion criteria strengthened the study design
by excluding patients who had previously received
maintenance therapy and those with a previous
COPD-related hospitalization or ED visit. Patients
with asthma were not excluded from the study sam-
ple because of the high overlap of comorbid asthma
and COPD and the challenges associated with dis-
cerning between the two conditions without clinical
data. The adjustment of baseline differences to obtain
valid drug cohort comparisons can be considered to
have been done correctly to the extent that appropri-
ate variables were used to capture the characteristics.
Adjustment in this study is only limited by the ability
to capture these characteristics accurately, and re-
sidual confounding may exist if the underlying sever-
ity is not adequately captured by these proxy
measures, especially unobservable confounders. How-
ever, the direction of the results shows a low likeli-
hood of any selection bias, as the FSC cohort was
more severe than the AC cohort at baseline.
Misclassification bias may exist in any claims-based study
due to miscoding or under-coding of claims. However, the
likelihood of this bias in the present study is low, as all out-
comes required a primary diagnosis of COPD, where the
probability of miscoding is low due to reimbursement
requirements. The outcome of a moderate COPD exacer-
bation was defined as a physician visit with a diagnosis of
COPD plus an OCS or antibiotic within 5 days. The re-
quirement of drug therapy within 5 days has been previ-
ously used [10, 11], is conservative, and increases the
likelihood that the medication was associated directly with
the COPD-related physician visit. The proportion of
patients with an exacerbation who also had a
hospitalization or ED visit was also reported, but could not
be stratified by the proportion of patients in the intensive
care unit (which would indicate a more severe exacerba-
tion), due to the small sample size of hospitalized patients.
The study design applied variable lengths of follow-up to
preserve sample sizes, and the time-dependent model
allowed for a completer rather than an intent-to-treat ana-
lysis. This type of an analysis also allows for censoring at
the time of treatment switch or discontinuation of the
index medication, thus ensuring that the outcome is related
to the exposure. Finally, results of this study are
generalizable only to a specific subset of COPD patients en-
rolled in a commercial managed care population, and the
inclusion criteria applied to increase the internal validity of
this study may reduce the generalizability of its findings.
Conclusions
Use of maintenance therapy in patients with moderate
COPD exacerbations is less than optimal. This study pro-
vides data to differentiate costs and outcomes between 2maintenance therapy options, FSC and ACs. Initiation of
FSC is associated with a significantly lower risk of subse-
quent COPD exacerbations, without an increase in total
costs, compared to ACs in moderate COPD exacerbations.
These data provide useful information for prescribers and
health policy decision makers in the selection of mainten-
ance therapies that reduce COPD exacerbations, without
increasing COPD-related medical costs. Further research
should seek to validate these findings using lung function
data, in order to determine the clinical severity level of the
patient population.
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